|
To
buy or not to buy
Indian generic companies are acquiring their way to success
and the trend seems to be inevitable. Katya Naidu finds out
why generics and acquisitions go together.
Upfront
'Quality
should be as good as the best'
Mankind Pharma has some special plans. It has forayed into
OTC business with its division Special Mankind. Sushmi Dey
explores the move, in conversation with R C Juneja, Managing
Director.
For
a healthy cause
While safety is mandatory in all walks of life, a healthcare
worker's safety is the least of all concerns.
Upcoming
Events
Sun
acquires Taro for $454 mn
Sun Pharmaceutical has acquired Taro Pharmaceuticals for $454
million in an all cash deal. Taro is a multinational generic
manufacturer with established subsidiaries, manufacturing
and products across US, Israel and Canada.
Avesthagen
and Manipal Acunova join hands
Avestha Gengraine Technologies has signed an MOU with Manipal
Acunova (a collaborative venture between the Manipal Education
and Medical Group International India, and AcuNova Life Sciences).
Intas
partners with Viropro
Ahmedabad-based Intas Biopharmaceuticals (IBPL) and Viropro
signed an MoU to jointly explore the possibilities of production
of an undisclosed molecule.
Glenmark
to market more generics
Glenmark Pharmaceuticals received USFDA approval to market
Pravastatin Sodium oral tablets 10 mg, 20 mg and 40 mg. It
is a generic version of Bristol Myers Squibb brand Pravachol
that has annual sales of over $861 million.
Torrent
launches obesity drug
Ahmedabad based healthcare major, Torrent Pharma has launched
Rimonabant, an anti-obesity molecule, for the first time in
India under the brand name Rimoslim.
J&J
opens R&D facility in Mumbai
Janssen-Cilag and Johnson & Johnson Pharmaceutical R&D
(J&JPRD) celebrated the opening of an extended and renovated
Analytical and Pharmaceutical Development Center, in Mumbai.
Govt
pitches in for AIDS vaccine
The Department of Biotechnology (DBT), Ministry of Science
& Technology, Government of India and the International
AIDS Vaccine Initiative (IAVI) signed an agreement to design
HIV vaccine candidates.
Wockhardt
launches insomnia drug Zolpidem in the US
Wockhardt received USFDA approval for marketing Zolpidem tablets
(the generic version of brand Ambien) in the US.
Lupin
signs MoU with Symbiotec
Lupin signed an MoU with Symbiotec Pharmalab, an Indian company
that focuses on steroids, for a joint venture by making an
equity investment in Symbiotec for a majority stake.
|
